Table 1.
In vitro activities of allopurinol derivatives against human hepatoma carcinoma 7402 and 7221 cell lines.
| Compounds | IC50(μM) a | |
|---|---|---|
| BEL-7402 | SMMC-7221 | |
| 17-AAG | 12.4 ± 0.1 | 9.85 ± 0.08 |
| 1 | 18.7 [19] | 9.03 [19] |
| 3 | >100 b | >100 b |
| 4 | 25.5 ± 0.4 | 35.2 ± 0.4 |
| 5a | >100 b | >100 b |
| 5b | >100 b | >100 b |
| 5c | >100 b | >100 b |
| 5d | >100 b | >100 b |
| 5e | >100 b | >100 b |
| 5f | >100 b | >100 b |
| 5g | >100 b | >100 b |
| 6 | >100 b | >100 b |
| 7 | >100 b | >100 b |
| 8a | 66.61 ± 0.62 | >100 b |
| 8b | >100 b | 81.46 ± 0.78 |
| 8c | >100 b | >100 b |
17-AAG: Tanespimycin. a IC50 value represents the drug concentration required to inhibit cancer cell replication by 50%. b The compounds were tested up to a concentration of 100 μM.